Bemarituzumab Biosimilar - Research Grade

Human

FGFR2b

>1mg/ml

Human IgG1

Aprutumab Biosimilar - Research Grade (ICH5052)

https://www.imgt.org/mAb-DB/

ICH3002

P21802

Blue ice

This product is a research-grade, unconjugated recombinant analog of bemarituzumab, an anti-FGFR2b antibody, supplied as a fully human IgG1 built around the fibroblast growth factor receptor 2 IIIb (FGFR2b) target. It is intended strictly for research use only and is not the clinical therapeutic; it is not for human or veterinary use. The molecule reproduces the antigen-binding specificity of the originator so investigators can study FGFR2b engagement, ligand blockade, and Fc-dependent effector biology in defined systems. As a human IgG1 it carries an intact Fc region, making it useful for interrogating ADCC and complement pathways and as a scaffold in antibody-drug conjugate (ADC) development workflows. Typical applications include positive and isotype-matched controls, binding and neutralization assays, receptor-internalization studies, and preclinical in-vitro or ex-vivo models. It is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support in-vivo-standard and screening-scale work. All content here is guidance for ichorbio to review. FGFR2b is the epithelial-lineage IIIb splice isoform of fibroblast growth factor receptor 2 (FGFR2; UniProt P21802), a single-pass transmembrane receptor tyrosine kinase. Alternative splicing of the third immunoglobulin-like domain generates the IIIb (epithelial) and IIIc (mesenchymal) isoforms, which differ in ligand selectivity; FGFR2b preferentially binds FGF7, FGF10, and FGF22. Ligand binding, aided by heparan sulfate, drives receptor dimerization, trans-autophosphorylation of the intracellular kinase domain, and downstream RAS-MAPK, PI3K-AKT, and PLCgamma signaling that regulates epithelial proliferation, differentiation, and survival. FGFR2 gene amplification and FGFR2b protein overexpression occur in a subset of gastric and gastroesophageal adenocarcinomas and some other epithelial tumors, where the receptor can act as an oncogenic driver, making isoform-selective FGFR2b targeting of interest.

FGFR-2, K-sam, KGFR, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, BEK

Detects human FGFR2b. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bemarituzumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Bemarituzumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Bemarituzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bemarituzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Bemarituzumab that binds human FGFR2b.